Table 5.
Stratified analysis of OVCF incidence by interactions with age, hypertension, diabetes mellitus, and levels of vitamin B12, folate, and homocysteine.
| Variables† | CD320 rs9426 CC vs. CT+TT | TCN2 rs10418 CC vs. CT+TT | SLC19A1 rs1051296 GG vs. GT+TT | SLC19A2 rs16862199 CC vs. CT+TT | ||||
|---|---|---|---|---|---|---|---|---|
| AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | |
| Age | ||||||||
| <69 | 1.000 (reference) | 0.383 (0.133––1.104) | 1.000 (reference) | 1.257 (0.479–3.301) | 1.000 (reference) | 3.782 (1.210–11.817) | 1.000 (reference) | 1.257 (0.479–3.301) |
| ≥69 | 0.642 (0.334–1.234) | 2.101 (0.907–4.868) | 1.057 (0.557–2.004) | 1.489 (0.638–3.473) | 5.132 (1.468–17.939) | 2.578 (0.810–8.208) | 1.057 (0.557–2.004) | 1.489 (0.638–3.473) |
| Hypertension | ||||||||
| No | 1.000 (reference) | 1.485 (0.640–3.446) | 1.000 (reference) | 2.125 (0.829–5.448) | 1.000 (reference) | 1.268 (0.517–3.110) | 1.000 (reference) | 2.125 (0.829–5.448) |
| Yes | 0.911 (0.469–1.768) | 0.966 (0.372–2.512) | 0.900 (0.469–1.726) | 0.963 (0.392–2.367) | 0.879 (0.289–2.670) | 0.938 (0.372–2.367) | 0.900 (0.469–1.726) | 0.963 (0.392–2.367) |
| Diabetes mellitus | ||||||||
| No | 1.000 (reference) | 1.270 (0.646–2.496) | 1.000 (reference) | 1.781 (0.881–3.600) | 1.000 (reference) | 1.257 (0.630–2.510) | 1.000 (reference) | 1.781 (0.881–3.600) |
| Yes | 0.851 (0.310–2.340) | 1.273 (0.301–5.379) | 1.301 (0.486–3.477) | 0.543 (0.113–2.621) | 1.492 (0.368–6.038) | 0.847 (0.261–2.744) | 1.301 (0.486–3.477) | 0.543 (0.113–2.621) |
| Vitamin B12a | ||||||||
| >395 pg/mL | 1.000 (reference) | 1.242 (0.653–2.362) | 1.000 (reference) | 1.259 (0.646–2.454) | 1.000 (reference) | 1.064 (0.561–2.018) | 1.000 (reference) | 1.259 (0.646–2.454) |
| ≤395 pg/mL | 0.845 (0.215–3.313) | 1.524 (0.129–18.010) | 0.469 (0.098–2.255) | 2.495 (0.331–18.782) | N/A | 0.784 (0.201–3.056) | 0.469 (0.098–2.255) | 2.495 (0.331–18.782) |
| Folatea | ||||||||
| >4.59 nmol/L | 1.000 (reference) | 1.097 (0.520–2.315) | 1.000 (reference) | 1.575 (0.740–3.351) | 1.000 (reference) | 1.028 (0.498–2.120) | 1.000 (reference) | 1.575 (0.740–3.351) |
| ≤4.59 nmol/L | 3.219 (1.418–7.307) | 7.307 (1.975–27.033) | 4.290 (1.911–9.629) | 3.085 (0.914–10.411) | 2.022 (0.469–8.730) | 3.589 (1.440–8.950) | 4.290 (1.911–9.629) | 3.085 (0.914–10.411) |
| Homocysteinea | ||||||||
| <12.68 μmol/L | 1.000 (reference) | 0.931 (0.456–1.900) | 1.000 (reference) | 1.810 (0.898–3.649) | 1.000 (reference) | 1.129 (0.570–2.237) | 1.000 (reference) | 1.810 (0.898–3.649) |
| ≥12.68μmol/L | 1.020 (0.335–3.103) | 5.760 (1.480–22.417) | 2.911 (1.100–7.704) | 0.861 (0.168–4.425) | 3.100 (0.492–19.542) | 1.286 (0.434–3.807) | 2.911 (1.100–7.704) | 0.861 (0.168–4.425) |
† Odds ratio adjusted by age, gender, hypertension, and diabetes mellitus. OVCF, osteoporotic vertebral compression fracture. a Cut–offs were set at the bottom 15% for vitamin B12 (395 pg/mL) and folate (4.59 nmol/L) and at the top 15% for homocysteine (12.68 umol/L) for both osteoporosis patients and controls.